Promethazine vs. Lorazepam for Treatment of Vertigo
Information source: Shahid Beheshti Medical University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Peripheral Vertigo.
Intervention: Promethazine (Drug); Lorazepam (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Shahid Beheshti Medical University
Summary
This study was a prospective, randomized, double-blind, parallel group clinical trial
designed to compare the efficacy of intravenous (IV) promethazine and lorazepam for the
treatment of peripheral vertigo in Emergency Department setting.
Clinical Details
Official title: Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Mean change in vertigo intensity.
Secondary outcome: Efficacy and Safety outcome measures (nausea change-second dose-adverse events).
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Aged 18 years or older
- Background history of positional vertigo
Exclusion Criteria:
- Unable to provide informed consent
- Pregnant or possibly pregnant
- Known allergy to study medications
- Use of antiemetic agents in the previous 24 hours
- Evidence of drug-induced vertigo or orthostatic hypotension
- Central pathologies/central origin for vertigo
Locations and Contacts
Department of Neurology, Emam Hossein Hospital, Tehran, Nezam Abad 17666-33815, Iran, Islamic Republic of
Additional Information
Starting date: April 2013
Last updated: June 13, 2013
|
